79.02 USD
-0.63 (-0.79%)
78.99 USD
-0.03 (-0.04%)
Taking everything into account, RVMD scores 2 out of 10 in our fundamental rating. RVMD was compared to 530 industry peers in the Biotechnology industry. RVMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RVMD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year RVMD has reported negative net income.
RVMD had a negative operating cash flow in the past year.
RVMD had negative earnings in each of the past 5 years.
RVMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RVMD has a Return On Assets of -26.65%. This is in the better half of the industry: RVMD outperforms 69.81% of its industry peers.
RVMD has a Return On Equity of -37.58%. This is in the better half of the industry: RVMD outperforms 72.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
RVMD has more shares outstanding than it did 5 years ago.
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 12.35 indicates that RVMD is not in any danger for bankruptcy at the moment.
RVMD's Altman-Z score of 12.35 is amongst the best of the industry. RVMD outperforms 84.15% of its industry peers.
RVMD has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
RVMD has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: RVMD underperforms 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 12.35 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
RVMD has a Current Ratio of 8.05. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD has a better Current ratio (8.05) than 74.72% of its industry peers.
A Quick Ratio of 8.05 indicates that RVMD has no problem at all paying its short term obligations.
The Quick ratio of RVMD (8.05) is better than 74.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.05 | ||
| Quick Ratio | 8.05 |
3. Growth
3.1 Past
The earnings per share for RVMD have decreased strongly by -44.01% in the last year.
RVMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 14.00% on average over the next years. This is quite good.
RVMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 454.63% yearly.
EPS Next Y-59.96%
EPS Next 2Y-35.33%
EPS Next 3Y-18.97%
EPS Next 5Y14%
Revenue Next Year1279.08%
Revenue Next 2Y959.84%
Revenue Next 3Y770.59%
Revenue Next 5Y454.63%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as RVMD's earnings are expected to decrease with -18.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.33%
EPS Next 3Y-18.97%
5. Dividend
5.1 Amount
No dividends for RVMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
79.02
-0.63 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.45%
Inst Owner Change0%
Ins Owners1.85%
Ins Owner Change-2.21%
Market Cap15.28B
Revenue(TTM)N/A
Net Income(TTM)-600.09M
Analysts87.41
Price Target84.3 (6.68%)
Short Float %8.09%
Short Ratio6.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.02%
Min EPS beat(2)-12.79%
Max EPS beat(2)-11.24%
EPS beat(4)0
Avg EPS beat(4)-9.21%
Min EPS beat(4)-12.79%
Max EPS beat(4)-1.54%
EPS beat(8)1
Avg EPS beat(8)-7.65%
EPS beat(12)4
Avg EPS beat(12)-2.45%
EPS beat(16)6
Avg EPS beat(16)-2.06%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.72%
PT rev (3m)9.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)48.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.57 | ||
| P/tB | 10.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.17
EYN/A
EPS(NY)-6.54
Fwd EYN/A
FCF(TTM)-4.02
FCFYN/A
OCF(TTM)-3.94
OCFYN/A
SpS0
BVpS8.26
TBVpS7.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 277.69% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.05 | ||
| Quick Ratio | 8.05 | ||
| Altman-Z | 12.35 |
F-Score1
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)158.77%
Cap/Depr(5y)142.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
EPS Next Y-59.96%
EPS Next 2Y-35.33%
EPS Next 3Y-18.97%
EPS Next 5Y14%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1279.08%
Revenue Next 2Y959.84%
Revenue Next 3Y770.59%
Revenue Next 5Y454.63%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.61%
EBIT Next 3Y-28.97%
EBIT Next 5Y7.47%
FCF growth 1Y-158.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.07%
OCF growth 3YN/A
OCF growth 5YN/A
REVOLUTION MEDICINES INC / RVMD FAQ
What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (RVMD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RVMD.
What is the valuation status for RVMD stock?
ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (RVMD). This can be considered as Overvalued.
How profitable is REVOLUTION MEDICINES INC (RVMD) stock?
REVOLUTION MEDICINES INC (RVMD) has a profitability rating of 1 / 10.
How financially healthy is REVOLUTION MEDICINES INC?
The financial health rating of REVOLUTION MEDICINES INC (RVMD) is 5 / 10.
What is the expected EPS growth for REVOLUTION MEDICINES INC (RVMD) stock?
The Earnings per Share (EPS) of REVOLUTION MEDICINES INC (RVMD) is expected to decline by -59.96% in the next year.